N/A N=188 Design Validation of Toric Contact Lenses in Senofilcon A With a Blue-Blocking Chromophore
Visual Acuity
Primary: Distance Monocular logMAR Visual Acuity — -0.107; -0.104 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=47 Blood Flow Restriction Training (BFR) in an Adolescent Population
Blood Flow Restriction · ACL Tear · ACL Injury
Primary: Isometric Quad Strength Peak Torque — 1.83; 1.31; 2.45; 2.1 Nm/kg
N/A N=532 A Text-based Reduction Intervention for Smokeless Tobacco Cessation
Smokeless Tobacco Cessation
Primary: Number of Participants Who Did Not Use Chew/Dip in the Past 7 Days (Quit) — 61; 56 Participants — p=0.5384
N/A N=452 Phone Coaching and Internet-delivered Weight Loss
Obesity
Primary: Percent Weight Change at 4 Months — -6.2; -7.0; -4.5 percent change
N/A N=32 Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage
Hypertension
Primary: Change in Systolic Blood Pressure — -7.5 mmHg — p=0.03232
N/A N=20 Clinical Evaluation of the Zynex Monitoring System, Model CM-1600
Fluid Loss
Primary: CM-1600 Ability to Detect Minor Blood Loss — 8.0 Percent change in RI
Phase 2 N=87 A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Leukemia, Lymphoid · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell
Primary: Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee — 71.4 Percentage of participants
Phase 4 N=6 Metabolism of 0.35mg Norethindrone vs 5mg Norethindrone Acetate
Contraception
Primary: Serum Concentration of Norethindrone — 15.69; 2.28; 13.56; 2.50 ng/ml
N/A N=352 Population Effects of MI on Pediatric Obesity in Primary Care
Pediatric Obesity
Primary: Percent Distance From the Sex-age Specific 95th Percentile — 106.4; 102.7 % distance from 95th percentile
Phase 2 N=32 Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
T-Cell Lymphoma Relapsed · T-Cell Lymphoma Refractory
Primary: Best Overall Response Rate During the First 8 Cycles of Treatment — 5 Participants
Phase 3 N=511 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Head and Neck Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) — 46.9…
Phase 2 N=21 Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS) · Hematopoietic Stem Cell Transplant (HSCT)
Primary: Number of Non-relapsed Deaths by 100 Days Post-transplant in Pediatric Patients Receiving a Myeloablative or Reduced-intensity Preparative Regimen Prior to HSCT for…
Phase 3 N=267 A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
Obesity
Primary: Mean Percent Change in Body Weight — -17.8; -22.7; -1.7 Percent change — p=<0.001
Early Phase 1 N=7 Operant H-reflex Down-conditioning of Rectus Femoris in Post-stroke Stiff Knee Gait
Training
Primary: Percentage Change From Baseline in RF H-reflex Magnitude — -43.82 percentage change in reflex size
Phase 4 N=55 Total Joint Arthroplasty and Sleep
Primary Total Hip Arthroplasty · Primary Total Knee Arthroplasty
Primary: Epworth Sleepiness Scale (ESS) — 7.73; 7.81; 8.36; 7.31 score on a scale